For all patients with BC who do not distinguish the PIK3CA mutation type, because of the relatively expensive price of genotype detection, a PI3K inhibitor is recommended as a therapeutic strategy, which may produce a curative effect. The gene discussed is PIK3CA; the disease is breast cancer.